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Abstract 
 
Ischemic heart failure is the leading cause of death in the world. The disease is caused by coronary heart 
disease, in which the narrowed coronary arteries limit oxygen- and nutrient-rich blood from reaching the 
myocardial tissue. Obstructed arterial blood flow can cause myocardial necrosis and scarring. Scar tissue is 
non-contractile and poorly elastic. It can thus compromise the pumping capacity of the heart. Current medical 
and interventional therapies have only very limited efficacy to reduce myocardial scarring. Preclinical and 
clinical research efforts are underway to generate myocardial scar-reducing and regenerative therapies. 
 
In the field of cardiac cellular therapies, the delivery of cells has conventionally been based on 
intramyocardial injections. However, epicardial patches have been demonstrated to reduce scarring and 
promote myocardial healing. In addition to merely being a carrier or cover for the cellular transplant, the 
biomembrane of the patch can also be considered as an active element for the patch’s therapeutic activity. Thus, 
the properties of the biomembrane can have a major impact on both the cellular and the therapeutic tissue 
response. 
 
The aim of this Master's thesis was to build a standardized test set up to study the properties of the 
biomembrane. Biomembrane permeability to small (glucose, lactate) molecules and different size proteins was 
investigated. In addition, the set up was modified to enable the investigation of biomembrane properties on the 
survival of the grafted cells. Finally, the test set up was evaluated by studying the properties of ProxiCorTM, the 
biomembrane currently used together with autologous atrial micrografts (AAMs) in epicardial patch. 
 
As a result, the set up was successfully constructed and characterized. The ProxiCorTM membrane 
demonstrated permeability to both small molecules and proteins, and a stable pH was maintained across the 
membrane. ProxiCorTM enabled traverse serum-induced proliferation of cells compared to the control 
impermeable membrane. Taken together, these results prove the functionality of the test set up and thus support 
its further development. 
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Tiivistelmä  
 
Iskeeminen sydämen vajaatoiminta on maailman johtava kuolinsyy. Sairauden aiheuttaa pitkäaikainen 
sydänlihaskudoksen hapen ja ravintoaineiden puute, jonka taustalla on usein sepelvaltimotauti. Tukkeuma 
sepelvaltimoissa estää hapen ja ravintoaineiden pääsyn sydänlihaskudokseen ja voi täten johtaa 
sydännekroosiin ja arpeutuneeseen sydänlihaskudokseen. Arpeutunut sydänkudos menettää joustavuutensa ja 
täten sydämen pumppausteho pienenee johtaen sydämen vajaatoimintaan. Vaikka iskeemistä vajaatoimintaa 
voidaan itsessään hoitaa monin eri tavoin ei arpeutuneelle kudokselle ole toistaiseksi olemassa tehokasta 
hoitomuotoa. Prekliinisiä ja kliinisiä tutkimuksia uusista hoitomuodoista on meneillään arpikudosta parantavan 
hoidon löytämiseksi 
 
Solututkimuksissa sydänlihaskudoksen päälle asetettavien epikardiaalisten paikkojen on osoitettu lisäävän 
siirrettyjen solujen eloonjäämistä ja jäämistä sydänkudokseen sekä tehostavan parakriinisten vaikutusten tehoa 
verrattuna perinteisiin injektiohoitoihin. Soluja tukevan vaikutuksen lisäksi epikardiaalisissa paikoissa käytetty 
biomembraani on tärkeässä osassa paranemisprosessia ja sen ominaisuuksilla on suuri vaikutus 
hoitovasteeseen. 
 
Tämän maisterintutkielman tarkoituksena oli rakentaa standardoitu koejärjestely, jonka avulla voidaan 
vertailla biomembraanien ominaisuuksia, kuten läpäisevyyttä pienille molekyyleille (glukoosi ja laktaatti), sekä 
erikokoisille proteiineille. Myös biomembraanin ominaisuuksien vaikutuksia siirretyistä soluista saataviin 
vasteisiin voitiin tutkia koejärjestelyä muokkaamalla. Koejärjestelyä testattiin tutkimalla ProxiCorTM-
biomembraania, jota käytetään eteiskorvakkeen soluista kehitetyssä epikardiaalisessa mikrosiirteessä. 
Koejärjestely oli onnistunut ja sen avulla suoritettu ProxiCorTM-membraanin koestus paljasti membraanin 
olevan läpäisevä sekä pienille molekyyleille että proteiineille. ProxiCorTM-membraanin käyttö myös tasasi 
pH:ta tutkimusasetelmassa. Lisäksi ProxiCorTM-membraanin käyttö mahdollisti seerumin indusoiman solujen 
jakautumisen läpäisemättömään kalvoon verrattuna. Saadut tulokset todistavat rakennetun koejärjestelyn 
toimivuuden ja tukevat täten sen jatkokehitystä. 
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Abbreviations 
AAMs autologous atrial micrografts 
ACC/AHA The American College of Cardiology and American Heart Association 
ACE angiotensin-converting enzyme 
ARB angiotensin-receptor blocker 
BMMNC bone marrow mononuclear cell 
CABG coronary artery bypass grafting 
CAD coronary artery disease 
CSC cardiac stem cell 
EDV end-diastolic volume 
EF ejection fraction 
EPC endothelial progenitor cell 
ESC European Society of Cardiology 
ESV end-systolic volume 
FBS fetal bovine serum 
HDL high-density lipoprotein 
HEK-293 human embryonic kidney 293 cells 
HF heart failure 
HFmEF heart failure with mid-range ejection fraction  
HFpEF heart failure with preserved ejection fraction 
HFrEF heart failure with reduced ejection fraction 
HSC hematopoietic stem cell 
IC intracoronary 
IHD ischemic heart disease 
IM intramyocardial 
IV intravenous 
  
 
 
 
 
LDL low-density lipoprotein 
LVEF left ventricular ejection fraction 
MWCO molecular weight cut-off 
MI myocardial infarction 
MSC mesenchymal stem cell 
MW molecular weight 
PLA poly (lactic acid) 
RAAS renin-angiotensin-aldosterone system 
SIS-ECM small intestine submucosa extracellular matrix 
SM skeletal myoblast
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1. Background  
1.1. Ischemic heart disease 
1.1.1. Atherosclerosis and ischemic heart disease 
Cardiovascular diseases, including ischemic heart disease (IHD) and heart failure (HF), are the 
leading causes of death worldwide (WHO, 2018). Annually, they are estimated to cause over 3.9 
million deaths in Europe and exert an €210 billion burden on the healthcare costs in the European 
Union (Timmins et al., 2018). 
In IHD, the flow of blood in coronary arteries is restricted. This restriction, usually caused by 
atherosclerosis, inhibits the transport of oxygen and nutrients to the heart tissue, ultimately leading 
to cell death and tissue damage. Eventually, atherosclerosis develops in everyone over time, but the 
development rate is determined by individual risk factors such as genetic predisposition or 
abnormalities, sex, age, cholesterol levels, type 2 diabetes, hypertension, and smoking (Kovanen & 
Pentikäinen, 2016). 
Atherosclerosis occurs under the endothelium in the inner layer (intima) of blood vessels, and 
the arterial branch points are especially favorable for disease development (Kovanen & Pentikäinen, 
2016). The most important event in the development of atherosclerosis is the accumulation of low-
density lipoproteins (LDLs) into the intima (Figure 1). This accumulation begins already in 
childhood and continues throughout life. 
Small amount of LDL enters the intima where the lack of capillaries or lymphatic system, and 
the attachment of the positively charged surface-proteins of the circulating cholesterol transporter, 
ApoB-100, to the negatively charged extracellular proteoglycans promotes retention of the LDL 
particles (Pentikäinen et al., 2000; Weber & Noels, 2011). In the intima the LDL particles are 
oxidized or modified by proteases or lipase enzymes. Macrophages in the intima recognize and 
phagocytose such modified particles, which are then scattered in the cells’ lysosomes. Most of the 
released cholesterol is transported to the cell membrane and out of the cell, bit some of it end up as 
cytoplasmic esterified accumulates. Over time more and more cholesterol esters and accumulations 
are formed, and the macrophages turn into foam cells. (Weber & Noels, 2011; Kovanen & 
Pentikäinen, 2016.) 
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Figure 1. Atherosclerosis is a progressive disease which starts with accumulation of low-density lipoprotein (LDL) 
particles and macrophages into the intima of arteries. Over time, macrophages turn into foam cells, which form a 
fibroatheroma together with extracellular fat droplets. Myocardial infarction occurs when a plaque ruptures causing a 
thrombus and clogging the artery. Reproduced with permission from Nelson et al. (2017) under the Creative Commons 
Attribution 4.0 International License. 
 
Some of the LDL particles are not phagocytosed by macrophages but end up in the 
musculoelastic layer of intima where these particles attach to elastin and form extracellular fat 
droplets. At the same time the foam cells die as a result of prolonged stress and cholesterol esters 
inside the cells are released. These free cholesterol esters together with fat droplets form a necrotic 
core. This intimal necrotic core keeps growing with the formation of new fat droplets and death of 
foam cells. (Kovanen & Pentikäinen, 2016.) 
Atheroma forms when the necrotic core is formed at the site prone to atherosclerosis. When 
atheroma is isolated from the bloodstream by connective tissue, it is called fibroatheroma. These 
fibroatheromas, or atherosclerotic plaques, are characteristic of atherosclerosis. While the 
fibroatheroma expands, the connective tissue grows over it as a result of collagen synthesis and 
division of activated smooth muscle cells. (Weber & Noels, 2011; Kovanen & Pentikäinen, 2016.) 
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Coronary artery disease (CAD) is caused by hardening and narrowing of the walls of the arteries 
due the plaque formation. This leads to a stage at which the availability of oxygen and nutrients to 
the heart muscle is insufficient. The long-term lack of oxygen to the heart muscle tissue, due CAD 
or other causes, is called IHD and it may manifest as exertional chest pains (angina pectoris), or 
myocardial infarction (MI). Angina pectoris is chest pain that most often occurs during physical or 
mental exercise strain but is quickly relieved at rest. MI occurs if the blood circulation in a specific 
part of the heart muscle is totally blocked by thrombosis of atherosclerotic plaque. This can be 
caused by erosion or rupture of the plaque. (Xu, Bendeck & Gotlieb, 2016; Kovanen, Pentikäinen & 
Mustonen, 2016.) 
The erosion-based thrombosis usually occurs with small fibroatheroma growing inward the 
artery. The rapid growth of plaque severely constricts the coronary artery, resulting in a situation 
where only a small blood clot can form a clog. This mechanism is behind chronic atherosclerosis 
with angina pectoris. A rupture ,in addition, is formed when a large fibroatheroma is growing 
outward of the artery, forming only thin connective tissue over the thrombogenic fibroadenoma 
tissue. The rupture reveals thrombogenic fibroadenoma tissue and activates the coagulation cascade, 
causing a large thrombus that clogs the artery. With ruptures, there are usually no symptoms in 
advance. (Kovanen, Pentikäinen & Mustonen, 2016.) 
Prolonged ischemia can cause sudden cardiac death arrhythmia or necrosis of myocardial tissue. 
With necrosis, the dead cells are removed by macrophages and later on replaced by granulation 
tissue and eventually collagenous scar deposited by fibroblasts and endothelial cells. The scarred 
tissue reduces heart function by ventricle wall thinning and remodeling, which eventually leads to 
HF. (Xu, Bendeck & Gotlieb, 2016; Richardson et al., 2015.) 
1.1.2. Heart failure and heart remodeling 
HF is a condition where the pumping capacity of the heart is decreased and thus the blood 
supply to the body is inadequate. HF is often a result of decreased capacity of the ventricles to fill or 
eject blood either through reduced efficiency of myocardial contraction or structural abnormality.  
After MI, the acute loss of myocardial cells results in an abnormal workload on the ventricle 
inducing dilatation which in turn renders the shape of the ventricle to a more spherical instead of 
elliptical form (Figure 2A). This remodeling does not only involve the infarcted area, but also the 
border zone and remote myocardium. Remodeling continues for months after the insult, and 
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eventually the changes in shape, orientation and length of the myocytes begins to affect the 
pumping capacity of the heart. (Bhatt, Ambrosy & Velazquez, 2017; Jessup & Brozena, 2003.) The 
spherical shape can also loosen the mitral leaflets and cause mitral regurgitation which further 
increases the workload of the left ventricle and, together with impaired conductivity and loss of 
elasticity from ischemia and fibrosis, contributes to the progression of disease (Abraham et al., 
2002; Jessup & Brozena, 2003). 
 
Figure 2. A. After myocardial infarction, the remodeling continues for months and changes the shape of the heart to 
more spherical. B. The heart failure with reduced ejection fraction (HFrEF) results in hypertrophied heart with normal 
left ventricular pumping capacity while the heart failure with preserved ejection fraction (HFpEF) has dilated heart and 
reduced contractility. Reproduced with permission from Jessup & Brozena (2003), Copyright Massachusetts Medical 
Society. 
 
Ejection fraction (EF) measures the fractional efficacy of the heart to pump out blood at full 
contraction (end-systolic volume, ESV) after a full relaxation (end-diastolic volume, EDV). It is 
expressed as the percentage of the equation (EDV-ESV)/EDV. Heart failure can be divided into 
heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection 
fraction (HFpEF). The normal range of left ventricular ejection fraction (LVEF) is between 50% to 
70%. An LVEF measurement under 40% is classified as HFrEF, while measurements of 41-49% 
are considered as borderline or mid-range HF (HFmEF). (Ponikowski et al. 2016.) HFpEF is 
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usually caused by thickening or stiffening of the left ventricle wall, resulting in a normal left 
ventricular contractility. Remodeling after MI more often results in a spherical shape of the heart 
with thin left ventricular walls and reduced LVEF (Figure 2B). (Jessup & Brozena, 2003.) 
Myocardial dysfunction often activates the sympathetic nervous system and increases the 
neurohormonal activity (Bhatt, Ambrosy & Velazquez, 2017; Liem et al., 2014). This activation is a 
compensatory mechanism for reduced cardiac output and aims to raise the blood pressure. The most 
well-recognized mechanism is the renin-angiotensin-aldosterone system (RAAS). (Bhatt, Ambrosy 
& Velazquez, 2017; Jessup & Brozena, 2003.) Commonly, patients with HF have been treated with 
drugs such as beta-blockers, angiotensin-converting enzymes (ACEs), and angiotensin-receptor 
blockers (ARBs), which all either directly or indirectly affect the RAAS system (Bhatt, Ambrosy & 
Velazquez, 2017; Jessup & Brozena, 2003). However, Vergaro et al. (2019) demonstrated that 
neurohumoral activation occurs only in a subset of patients with HFpEF or HFmEF, and therefore 
neurohumoral antagonism is useful especially for patients with HFrEF but only for selected patients 
with HFpEF or HFmEF . In addition to RAAS, several vasoactive substances, such as 
norepinephrine and natriuretic peptide, are synthesized within the myocardium and thus those can 
alter the workload of the ventricle both in autocrine and paracrine manner (Bhatt, Ambrosy & 
Velazquez, 2017; Jessup & Brozena, 2003). Workload can also be altered with invasive assembly of 
compression assistants such as biomembranes or cardiac compression devices (Naveed et al., 2018). 
1.2. Current treatment of heart failure 
Treatment of HF depends on the severity of disease. The American College of Cardiology 
(ACC) and American Heart Association (AHA) (Yancy et al., 2017) and European Society of 
Cardiology (ESC) (Ponikowski et al., 2016) have published guidelines for the management of HF. 
In the ACC/AHA guidelines, the disease has been classified into four stages describing the 
progression of disease (Figure 3). In stage A, the patients have high risk factors without symptoms 
and in most severe stage D, the patients require immediate intervention. Thus, the disease is 
progressing, and by definition patients cannot go back to the earlier stage after entering the next 
one. 
Especially in stages A and B, lifestyle changes the center of the treatment. Weight loss, physical 
activity, healthier food choices, and quitting smoking are the first steps to prevent disease onset. 
These changes aim to reduce the levels of cholesterol and sugar in circulating blood and lower the 
blood pressure. However, not all patients achieve benefits by modifying only lifestyle and, in some 
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cases, medication is required. Already in stage A, statin therapy should be prescribed in addition to 
dietary therapy to lower the serum cholesterol. ACE inhibitors and ARBs are used to prevent the 
production of angiotensin II or inhibit its receptor-mediated effects and thus to lower the blood 
pressure. (Yancy et al., 2017; Ponikowski et al., 2016.) 
 
Figure 3. Heart failure is progressive disease and can be classified into four different stages. Traditionally the treatment 
is based on the severity of the disease. Reproduced with permission from Jessup & Brozena (2003), Copyright 
Massachusetts Medical Society 
 
In stage B, there are structural changes like hypertrophy in the heart, but the patient remains 
without symptoms. This group also includes patients with previous MI, left ventricular systolic 
dysfunction or valvular heart disease. In stage B, ACE inhibitors and ARBs are routinely used for 
all patients. MI patients should also be prescribed with beta-blockers. Beta-blockers not only reduce 
heart rate by sympatholytic response but also decrease renin secretion in kidneys and thus lower the 
blood pressure. (Yancy et al., 2017; Ponikowski et al., 2016.) Beta-blockers can also enhance 
beneficial reverse remodeling of the myocardium (Khattar et al., 2001).  
Patients with structural changes in the heart and with previous or current symptoms are 
classified into stage C. The treatment in stage C varies largely between individuals. ACE inhibitors 
and beta-blockers are used for all patients but usually there is a need for dietary sodium restriction 
or diuretics. Aldosterone antagonists are used to help to maintain the cardiovascular homeostasis if 
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symptoms remain after other therapies or if patients cannot use ACE treatment because of side 
effects.(Yancy et al., 2017; Ponikowski et al., 2016.) Digoxin has traditionally been used with atrial 
fibrillation patients to increase the contractility by affecting the Na+/K+-ATPase pump in the 
myocardial cells and to provide symptomatic benefit. However, use of digoxin has recently been 
linked with higher mortality and morbidity (Aguirre Dávila et al., 2019), and the benefits of digoxin 
may only be limited to selected patients. Serum digoxin concentration over 1.2 ng/ml has also 
shown to have a potential to contribute to ventricular tachyarrhythmia and bradyarrhythmia 
(Rathore et al., 2003).  
In more advanced forms of stage C, invasive treatments come into play. Cardiac 
resynchronization treatment with a heart pacer is used with patients with present bundle-branch 
block. (Yancy et al., 2017; Ponikowski et al., 2016.) Pacers not only improve the left ventricular 
function but can also promote reverse remodeling (Gould et al., 2018). Percutaneous coronary 
intervention is used to open the blocked or narrowed arteries. In percutaneous coronary 
intervention, a small stent is usually implanted to a coronary artery to keep its lumen open. In 
coronary artery bypass by grafting (CABG), veins from lower limbs or arteries of the chest wall are 
used to circumvent blocked arteries and to supply blood to the myocardium.  
The most severe stage is D, where special intervention is needed. Inotropes are used to help 
maintain myocardial contractility with ventricular assist devices. Heart transplantation can also be 
considered. At this point, hospice is the final option if other treatments have not been successful. 
(Yancy et al., 2017; Ponikowski et al., 2016.) 
1.3. Cell therapies in the treatment of heart failure 
Even though there are several treatment options for HF, we still have no effective treatments 
that targetedly modify myocardial scar tissue (Liang et al., 2019). In 1993, Koh et al. were the firsts 
to attempt to solve the problem with stem cells by creating intracardiac grafts from murine 
cardiomyocyte-like tumor cells. So far, several preclinical studies and clinical trials have been 
conducted based on different cardiac and non-cardiac cell sources (Figure 4) (Pfister et al., 2014).   
In the early stages of disease, cell therapies may provide support to the arteries by modifying the 
inflammatory process. However, it is more likely that cell therapies redeem their place in the more 
advanced stages of disease in conjunction with invasive treatment. When considering autologous 
cellular therapies to elderly patients, one must take into account the age and the medical history of 
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the patient as these can have a great impact on the cells’ therapeutic capacities. Also, we still suffer 
from lack of knowledge about the cellular factors that affect or modify the magnitude of the 
therapeutic response and thus contribute to the success of treatment. 
 
 
Figure 4. The results with non-cardiac stem cells, such as skeletal myoblasts (SMs) or bone marrow derived 
mononuclear cells (BMMNCs) have been mixed or only modest. Studies with cardiac stem cells (CSCs) have been 
promising but the efficacy and safety still needs to be further investigated. Currently the research trend has shifted 
towards cell free therapies such as patches, extracellular vesicles or microRNAs. Reproduced from Cambria et al. 
(2017) under the Creative Commons Attribution 4.0 International License. 
 
Cell-mediated cardiac effects can be divided into two main categories: direct and paracrine 
effects. Direct effects consist of the niche-like environment provided by grafted cells and the 
transdifferentiation of these grafted cells into cardiomyocytes, endothelial cells and smooth muscle 
cells. These, together with recruitment and activation of resident stem cells, improve contractile 
performance. The recruitment and activation of resident stem cells is based on paracrine effects, 
which, in addition, play a role in reverse remodeling of myocardium by attenuating apoptosis, 
stabilizing scar formation by modulating matrix remodeling, and increasing capillary density by 
enhancing angiogenesis and vasculogenesis. (Pfister et al., 2014; Pagano et al., 2018.) In 2008, 
Korf-Klingebiel et al. reported secretome of bone marrow cells used in cardiac therapy, and in the 
same year Gnecchi et al. (2008) demonstrated that the beneficial effects of stem cell transplant 
depend more likely on paracrine factors secreted by grafted cells, rather than their differentiation. 
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The importance of paracrine factor has also sifted the research trend towards cell free therapies, 
which are based on small molecules such as microRNAs, extracellular vesicles, growth factors, and 
biomaterial patches (Cambria et al., 2017).  
1.3.1. Non-cardiac stem cells   
The first cells used in cardiac cell therapy were skeletal myoblasts (SMs) followed by bone 
marrow mononuclear cells (BMMCs), endothelial progenitor cells (EPCs), mesenchymal stem cells 
(MSCs) and hematopoietic stem cells (HSCs).  
SMs were the first cells entering the preclinical and clinical studies. Even though the SMs were 
shown to be resistant to ischemia and could be activated in response to muscle damage, in rodent 
models the SMs were not able to electrophysically couple to cardiomyocytes (Reinecke et al., 
2000). In clinical studies, the SMs were shown to increase the risk of ventricular arrhythmias due to 
the defective coupling (Abraham et al., 2002). This led to the termination of the SM investigation.  
Bone marrow-derived cells like BMMNCs, HSCs, and EPCs were widely studied cell sources 
due to their safety, high availability and easy isolation. The outcomes were mixed both in 
preclinical and clinical studies. Some clinical trials, such as TOPCARE-AMI or FINCELL, showed 
improvement in LVEF compared to control group while some trials, such as BONAMI and HEBE, 
reported no significant benefits (Hirsch et al., 2011; Leistner et al., 2011; Roncalli et al., 2011; 
Huikuri et al., 2008). In 2007, Zhang et al. suggested that the increase in angiogenesis due bone 
marrow cell treatment could be achieved through paracrine effects instead of myocardial 
differentiation.   
MSCs are located in all postnatal organs, including the heart and can be isolated from bone 
marrow, adipose tissue, peripheral blood, and synovial tissue. Preclinical trials with MSCs were 
promising and trials such as POSEIDON and MSC-HF yielded positive outcomes in myocardial 
function (Hare et al., 2012; Mathiasen et al., 2019). MSC efficacy and safety still needs to be further 
investigated.  
1.3.2. Cardiac stem cells  
In 2002, Hierlihy et al. showed that the adult heart retains undifferentiated cardiac stem cells 
(CSCs) and nowadays research has shifted towards these. The sources for mesodermal lineage 
CSCs are the primary heart field  the secondary heart field, and proepicardial organ. In addition to 
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these, there are ectodermal lineage-derived cells from cardiac neural crest. (Santini et al., 2016.) 
The best-known CSCs were identified by Beltrami et al. in 2003. They reported CSCs, which 
expresses c-Kit on their surface and proved to be clonogenic, self-renewing and multipotent. Later 
studies showed that these c-Kit+ -CSCs can be cardiomyogenic, originating from cardiac neural 
crest, or vasculogenic, originating from mesoderm (Hatzerigos et al., 2016). In the SCIPIO trial, the 
transplantation of c-Kit+-CPCs in patients with heart failure improved heart function, reduced 
infarct size, and increased viable tissue mass (Chugh et al., 2012). In 2017, Sharma et al. reported 
paracrine factors secreted by the c-Kit+ -CPCs after their transplantation in the infarcted 
myocardium and confirmed that the beneficial effects are due to paracrine pathways. In animal 
studies, c-Kit+ cells reduced infarct size and improved cardiac function through paracrine effects 
(Hodkinson et al., 2018). In addition, Sharma et al. noted that the paracrine factors secreted by 
rodent c-Kit+ -CPCs in comparison to human c-Kit+ -CPCs were different and thus the rodent 
models should not be used in studies for clinical applications. The cardiomyogenic availability of c-
Kit+ -CPCs has later been questioned and those are claimed to be primarily endothelial progenitors 
(Elhelaly et al., 2019).  
After observation of c-Kit+-CSCs, Laugwitz et al. (2005) reported Isl+ progenitor cells, which 
originate from both the secondary heart field and the cardiac neural crest, and can differentiate into 
several cell types, including cardiomyocytes and endothelial cells. In 2018, Foo et al. reported that 
injection of Isl+ cells into the hearts of NSG mice after MI preserved myocardial contractile 
function.  
In the epicardium, there are pools of undifferentiated progenitor cells which, in murine models, 
are identified by expression of platelet-derived growth factor receptor-a (PDGFRa) and/or stem cell 
antigen-1 (Sca-1). These PDGFRa+/Sca-1+ -CSCs are reported to form colony-forming units and 
are able to differentiate into osteogenic, adipogenic, and chondrogenic derivatives. (Chong et al., 
2011.) In 2019, Marunouchi et al. suggested that treatment with Sca-1+ cells preserved the cardiac 
pumping function and mitochondrial respiration better than c-Kit+ cells.   
1.3.3. Infusion techniques in the delivery of cells  
The cell delivery route is an important factor in the success of treatment. The most popular 
delivery routes are intramyocardial (IM), intracoronary (IC), and intravenous (IV) approaches 
(Figure 5).  
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Figure 5. In addition to infusion-based techniques, there are epicardial patches, which enhance the cell retention and 
survival in the implantation area (Davies et al., 2016). Creative credits Lynch P.J. under the Creative Commons 
Attribution 2.5 Generic License. 
 
The IM injections are targeted to the myocardium. Injection is usually directed to the border 
zone of the infarcted area, which has high impact on post-MI remodeling and where the blood 
supply ensures better survival of the injected cells (Kung et al., 2018; Olivetti et al., 1986). IM 
injections can be guided through the epicardium, endocardium or coronary vessels. While the 
epicardial IM injection is invasive and usually given during open heart surgery, endocardial IM 
injections can be performed with catheters through peripheral vessel access. Catheters are passed 
through peripheral vessels into the left ventricular cavity, where electromechanical methods are 
used to determine the border zone. While the endocardial procedure is less invasive than epicardial, 
uncontrolled electromechanical coupling has the potential to induce ventricular arrhythmias 
(Losordo et al., 2007). For trans-coronary IM injections, the catheter is passed from a peripheral 
vessel into the right atrium and from there to coronary sinus. While some studies report that IM 
approaches are the most efficient engraftments (George et al., 2008), other studies show that the 
grafted cells from IM injections are likely to form localized clusters within the myocardium 
(Fukushima et al., 2008), and that this heterogeneity may cause problems in conductivity and 
electrical impulse propagation resulting in generation of ventricular arrhythmias (Fukushima et al., 
2007). The problem occurs especially with SMs which are contractile but rarely form gap junctions 
with cardiomyocytes (Fukushima et al., 2008). 
In IC injection, the cell suspension is injected into the coronary circulation. The IC injection can 
be implemented using two different approaches; antegrade or retrograde. In the antegrade approach, 
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the catheter is inserted to a coronary artery from the proximal aorta while the retrograde approach 
uses coronary veins instead of arteria and thus enables cell delivery areas with lower arterial supply. 
The blood flow in the arteria or vein is blocked with an inflated balloon and the cells are injected to 
the distal side. Balloon is then deflated and the coronary flow is restored. Compared to IM 
approaches, IC injections are less invasive and most of the cardiologists are familiar with 
percutaneous technique. The major problem with IC techniques is poor cell retention in the 
injection area so that the cells are rapidly lost into the systemic circulation (Goussetis et al., 2006; 
Doyle et al., 2007). With IC techniques, there is also the risk of coronary embolism, especially 
when injecting larger cells such as MSCs (Vuillet et al., 2004).  
IV injections are less invasive and less expensive compared to IM and IC approaches, but the 
cell migration to and retention in the heart are limited (Aicher at el., 2003). While some MSC types 
appear to have higher cardiac homing rates than others (Kraitchman et al., 2005), new strategies 
must be developed to improve cardiac retention.   
1.3.4. Epicardial patches 
In addition to infusion techniques, cells can be delivered onto the heart’s outer surface, 
epicardially. Epicardial delivery can be achieved using, for example, cell sheets or epicardial 
patches, in which the cells are delivered with a biomembrane. An epicardial patch is then 
transplanted onto the myocardial tissue. While the epicardial technique as such requires open heart 
surgery, it offers distinct advantages over other delivery routes. In rat models, the cell retention and 
survival are increased compared to IM injections (Tano et al., 2014) and the paracrine molecules 
reduced fibrosis and increased angiogenesis even though the grafted cells were not reported to 
precipitate into cardiomyogenesis (Hamdi et al., 2014). In the advanced stages of disease, 
transplantation of the patch can be combined with implantation of a ventricular assist device and/or 
direct cardiac compression devices and thus support the circulation by compression and 
mechanically restrain the heart (Naveed et al., 2018; Xie et al., 2020). 
However, the scaffold, which is used in the patch, is not only just a passive structure supporting 
the patch and providing protection to the cells, but it can also be considered as an active contributor 
to the therapeutic effects resulting from the patch treatment. The biomaterial scaffold is not a 
permanent insert, and it will eventually be resorbed and degraded in the body. However, the 
degradation products may have a great impact on the patch microenvironment. The natural based 
scaffolds, such as traditional porcine small intestine submucosa extracellular matrix (SIS-ECM), are 
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biologically active, promoting cell adhesion and growth. The degradation products of SIS-ECM 
have been shown to be antimicrobial (Sarikaya et al., 2002), promote vascularization, and stimulate 
endothelial cell recruitment in vivo (Li et al., 2004). In addition to SIS-ECM, ECM bioscaffolds can 
be produced from other tissues sources, which are considered to have potential for cardiac repair 
and regeneration. Table 1 presents several natural based scaffolds, which are already commercially 
available.  
Table 1. A partial list of  commercially available ECM bioscaffolds. Reproduced with permission from Pattar, 
Hassanabad & Fedak (2019) under the Creative Commons Attribution 4.0 Lisence  
 
 
Bioscaffolds can also be fabricated from synthetic materials. The use of synthetic components 
may lead to improved surface properties and mechanical tolerance (Pattar, Hassanabad & Fedak, 
2019). However, some of the synthetic materials, such as the commonly used polyglycolic acid 
(PGA) and polylactic acid (PLA), are degraded through hydrolysis and yield acidic degradation 
products (Avérous, 2008). These degradation products may lower the microenvironment’s pH, 
cause necrosis of the target tissue cells and thereby inhibit or limit healing.  
In addition to just supporting the cell delivery, the membrane can be designed to release desired 
factors such as angiogenesis-enhancing agents or drugs upon degradation. E.g. in 2015, Wei et al. 
evaluated the epicardial delivery of follistatin-like 1 (Fstl1) protein into the injured heart in three-
dimensional collagen nanofibrillar patches with positive outcomes. However, the content of the 
patch can be more complex than just one specific agent. In 2017, Fleischer et al. reported a 
multifunctional cardiac patch which consists of various eletrospun albumin fiber layers with 
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different functions. The patch included substances such as cardiac cells, growth factors and anti-
inflammatory drugs and shared mechanical properties similar to heart. In the future, this kind of 
multilayer scaffold may be used to protect not only the heart but also other tissues, including the 
lung and the liver (Fleischer et al., 2017). 
1.3.5. Autologous atrial micrograft transplantation   
Atrial appendages are extensions to the atriums. They slightly increase the atrial volumes, and 
act as decompression chambers during ventricular contraction (Al-Saady, Obel & Camm, 1999). 
The atrial appendages have been used as sources for stem cells already in 2012 SCIPIO trial (Chugh 
et al., 2012). In 2013 Koninckx et al. identified new CSCs from the atrial appendages. These cells 
had high aldehyde dehydrogenase (ALDH) activity and expressed CD34 on the cell surface but 
lacked CD45 and c-Kit expression. These ALDHPOSCD34POSCD45NEG CSCs were named cardiac 
atrial appendage stem cells since they constituted a unique phenotype compared to the previously 
described CSCs. 
Cardiac atrial appendage stem cells are reported to promote angiogenesis and be able to 
differentiate into functional cardiomyocytes (Koninckx et al., 2013; Fanton et al., 2016). The 
autologous atrial micrografts (AAMs) treatment is harnessing these features to treat scarred 
myocardium after MI. The AAMs patch procedure has been presented in studies by Nummi et al. 
(2017) and Lampinen et al. (2017) (Figure 6). 
The AAMs patch is made in the operating room during on-pump CABG surgery. In the surgery, 
the central venous cannula of the heart-lung machine is inserted through the atrial appendage (El-
Sherief et al., 2013). The patient's medical history and clinical evaluation determine whether the 
right or left atrial appendage is used. With atrial fibrillation patients, who cannot use anticoagulant 
therapy, the left atrial appendage can be closed and amputated. Thus, for these patients it is natural 
to isolate the micrografts from the left atrium appendage. For patients without atrial fibrillation, the 
right atrium appendage is used for micrografting. During cannula insertion, a piece of atrial 
appendage is removed for the generation of micrografts and subsequent utilization in the AAMs 
patch. 
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Figure 6. During coronary artery bypass by crafting (CABG) surgery, a small piece of atrial appendage is removed and 
homogenized into micrografts. These micrografts are then placed over the biomembrane and mounted on the 
myocardial scar tissue. Picture reproduced from Lampinen et al. (2017), with permission from the copyright holder 
Elsevier (License number 4785240546664). AADC= atrial appendage derived cells. 
 
A tissue piece is mechanically homogenized into micrografts and these micrografts are placed 
over the biomembrane material to form a patch. The AAMs patch is mounted on the myocardial 
scar tissue identified preoperatively using cardiac magnetic resonance imaging (MRI). (Lampinen, 
2017; Nummi, 2017.) Under the AAMs patch, the micrografts produce paracrine factors as 
previously discussed. These factors, such as growth factors, cytokines and extracellular vesicles, act 
on the underlying damaged myocardium to facilitate cardiac repair and angiogenesis, as well as to 
activate antifibrotic signaling pathways. The AAMs patch has been shown in experimental animal 
studies to heal scar tissue and restore tissue elasticity (Xie et al., 2020).   
The currently used membrane in AAMs patch is the ProxiCor™ (Aziyo Biologics, Richmond, 
CA, USA), which is made of SIS-ECM. The ProxiCor™ is dense and considered to be 
impermeable. With this membrane it has been considered that the harmful metabolites produced by 
the cells of the graft, such as lactate, remain under the membrane, making the environment acidic 
and unfavorable to the cells. Meanwhile, outside the membrane the pericardium fluid contains a lot 
of energy-rich substances, such as glucose, which would be a natural source of energy for the 
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micrografts under the membrane (Figure 7). However, several studies (Gnecchi et al., 2008; Pfister 
et al., 2014; Pagano et al., 2018; Sharma et al., 2017) demonstrates that the positive effects of 
grafted cell are based on paracrine effects and thus the scaffold should retain the secreted proteins 
under the patch to achieve a positive effect on myocardial scar tissue. 
 
2. Aims 
Even if we know that biomembranes can have a tremendous impact on the cell responses in 
epicardial patches, the factors as well as information on how the biomembranes support healing, are 
still lacking attention. 
The aim of this Master’s thesis was to build a standardized test set up to study membrane 
properties. The test set up was evaluated by investigating the permeability of ProxiCor™ and to 
study how the biomembrane properties affect cell viability and proliferation when separated from 
the pericardial space and fluid in cardiac patches. 
Figure 7. A. With impermeable biomembrane, harmful metabolites retain under the patch making the 
environment acidic. The unfavorable environment affects the grafted cells and restrains the therapeutic effect 
from secreted proteins. B. With permeable biomembrane, the harmful metabolites can sift out of the patch and 
thus boosts the cell viability and the healing properties of grafted cells. 
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3. Materials and methods  
3.1. Membrane permeability test set up  
The membrane to be examined was placed into a 3.4 ml side-by-side diffusion chamber with 12 
mm orifice diameter (PermeGear Inc., Hellertown, PA, USA). The left chamber was called a donor 
cell and the right chamber a receptor cell. The donor cell was considered to mimic the space 
between the patch and the epicardial surface and the receptor chamber  was considered to mimic the 
space outside the patch (the pericardial extracellular fluid). Magnetic stirrers were inserted into both 
cells to maintain the movement of solutions. The test set up was kept at 37 °C with a water jacket 
heater. The diagram of the test set up is shown in Figure 8.B. In addition to ProxiCor™, Nunc™ 
polycarbonate membrane inserts (ThermoFischer Scientific, Waltham, MA, USA) with 0.4 µm 
pores were considered as positive control membrane and PARAFILM®  (Bemis Company Inc., 
Neenah, WI, USA) as a negative control membrane. 
To study small molecule movement, glucose and lactate were chosen as model molecules. 
Ringer's lactate solution (J67572, Alfa Aesar,Haverhill, MA, USA) was diluted with PBS 
(A099400100, Aniara Diagnostica, West Chester Township, OH, USA) to form a solution 
containing 2 mM lactate. D(+)-glucose (A16828, AlfaAesar) was dissolved with PBS to form a 
solution containing 5 mM D(+)-glucose. 
To study protein retention, 25 µl of Precision Plus Protein™ Standard (1610374, Bio-Rad 
Laboratories, Hercule, CA, USA) and 25 µl of Spectra™ Multicolor Low Range Protein Ladder 
(26628, ThermoFischer Scientific) were added to the lactate solution. The protein mixture covered 
the molecular weights from 1.7 kDa to 250 kDa. The lactate-protein solution was added into the 
donor cell and the glucose solution into the receptor cell.  
Measurements were conducted real-time for 24 hours. Glucose and lactate concentrations were 
measured with a LV5 biosensor (Jobst Technologies GmbH, Freiburg, Germany) and BioMON4 
software (v.4.15.0, Jobst Technologies GmbH) from the receptor cell. pH stability in the donor cell 
was controlled with WTW inoLab®  Multi 9310 IDS with SenTix®  Micro 900 electrode (Xylem 
Analytics, Weilheim, Germany) through a MultiLab®  Importer (v.1.22, Xylem Analytics). The 
protein movement was measured from the receptor cell as absorbance with Agilent 8453 
spectrophotometer (Agilent Technologies, Santa Clara, CA, USA) at the 280 nm wavelength. The 
layout of meters is presented in Figure 8A. 
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Figure 8. A. The decrease in glucose concentration and the increase in lactate concentration were measured from the 
receptor chamber with a biosensor. The protein movement into the  receptor chamber was  investigated as change in 
absorbance at 280 nm with a spectrophotometer. The stability of pH was monitored from the donor chamber. All 
measurements were conducted in real-time. B. The lactate and protein solution was inserted to the donor chamber, 
which was considered to mimic the space inside the patch. The glucose solution was inserted  into the receptor chamber, 
which was considered to mimic the space outside the patch. The test set up was kept at 37 ℃ with a water jacket heater 
and the movement of solutions were maintained with magnetic stirrers. C. HEK-293 cell solution was placed into the 
donor chamber and cell viability and cell cycle analysis were conducted after 24 h incubation. 
 
After the incubation, the solutions were collected from both chambers and concentrated with 
Microsep Advance Spin-ultracentrifugation units with 1 kDa molecular weight cut-off (MWCO) 
(MCP001C41, Pall Corporation, New York, NY, USA). Samples were then run through SDS-Page 
(80 V, 90 min.) to confirm by in-gel imaging using Coomassie Brilliant Blue R-250 (161-0436, 
Bio-Rad) the size of proteins on both sides of the membrane.  
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3.2. Cell viability and proliferation   
Human embryonic kidney 293 cells (HEK-293, ATCC®  CRL-1573™, LGC Standards GmbH, 
Wesel, Germany) were cultured in Leibovitz L-15 media (BE12-700F, Lonza Group AG, Basel, 
Switzerland) with 5 % fetal bovine serum (FBS) (Gibco™ 10500-065, ThermoFischer Scientific) , 
1 % L-Glutamine (Gibco™ 25030081, ThermoFischer Scientific), 1 % Antibiotic-antimycotic 
(Gibco™ 15240096, ThermoFischer Scientific) and 5 mM glucose (Gibco™ A24940-01, 
ThermoFischer Scientific) additions. Cells were cultured at +37 °C in an ambient humidified air 
atmosphere without CO2 supplementation. 
To determine the optimal conditions for viability and proliferation testing, the HEK-293 cell 
cultures were kept in serum starvation for four different periods (2 days, 3 days and 7 days). After 
serum starvation, four FBS additions of varying strength (0 % addition, 1% addition, 5 % addition 
and 10 % addition) were added to the culture flasks for 24 hours. A normal cell culture without 
serum starvation and with 5% FBS addition was kept as a control. The viability was measured after 
serum incubation with Countess™ II automated cell counter (Applied Biosystems™, 
ThermoFischer Scientific) with trypan blue staining and cell cycle analysis was conducted by BD 
Accuri™ C6 flow cytometer (BD Biosciences, Frankin Lakes, NJ, USA) with propidium iodide (PI) 
staining. The conditions with strongest effects on cell proliferation were chosen for further testing. 
A volume of 3.4 ml HEK-293 cell solution (6x106 cells/ml) was added to the donor chamber in 
Leibovitz L-15 media without serum addition. Leibovitz L-15 culture media with 10 % FBS 
addition was added into the receptor chamber (Figure 8C). The chambers were separated by a 
membrane under study. Cells and media were collected from donor and receptor chambers after a 
24-hour incubation. The cell viability was analyzed before and after incubation and cell cycle 
analysis was conducted after incubation. 
3.3. Data Analysis  
The movement rate of small molecules, protein retention and pH stability were analyzed with 
GraphPad Prism 8 (v8.4.1, GraphPad Software, San Diego, CA, USA ). After the identification of 
outliers, the glucose and lactate curves were smoothened against 15 neighbour measurements. The 
intensity of lines in the SDS-page were analyzed with ImageJ Fiji (Rev. 24.1.2020) (Schindelin, 
Arganda-Carreras & Frise et al., 2012). Cell viability information was analyzed with GraphPad 
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Prism 8 and the distribution of cell cycle phases was analyzed with BD FlowJo™ software (v10.6.2, 
BD Biosciences).  
4. Results  
4.1. Permeability of ProxiCor™  
4.1.1. Small molecule movement 
ProxiCor ™ permeability for small molecules was analyzed by measuring the changes in 
glucose and lactate concentrations from the receptor chamber. The stability of pH was also 
recorded. The permeability of ProxiCor™ was compared to the positive and the negative control 
membranes. As a result, the ProxiCor™ found to be permeable both for glucose and lactate. The pH 
remained stable regardless of the membrane .The results from glucose, lactate, and pH 
measurements are represented in Figure 9. 
4.1.2. Protein retention 
The protein movement from donor chamber to receptor chamber was inspected by measuring 
the changes in absorbance at 280 nm from receptor chamber every 5 minutes. The permeability of 
ProxiCor™ was compared to the positive and the negative control membranes. The results from 
absorbance measurements are represented in Figure 10. As the absorbance measurements with 
ProxiCor™ were higher than with positive control, the amount of proteins passed was not directly 
readable from the change in absorbance. Thus, the samples from donor and receptor chambers were 
run through SDS-page to investigate the proteins on both side of the membrane and further examine 
the size distribution of proteins passed through (Figure 11A). As a result, the ProxiCor™ found to 
be permeable also to proteins within studied range. 
As the absorbance measurements with ProxiCor™ were higher than with positive control, there 
was an assumption that ProxiCor™ itself releases proteins. To confirm that assumption, a piece of 
ProxiCor™ was incubated in 3,4 ml 0.9% NaCl (BP358-1, ThermoFischer Scientific) for 24 hours. 
After incubation the liquid was collected and concentrated and ran through SDS-page (Figure 11B). 
Results confirmed the assumption of released proteins. 
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Figure 9. A. Real-time measurements of glucose concentrations (mM) and  B. lactate concentrations (mM)  in the 
receptor chamber. In the biosensor, there was three pins for measure lactate and only one pin for measure glucose. Thus, 
the stabilization time of the biosensor affected the glucose measurement more than the lactate measurement, which was 
calculated as a mean value of all three pins. The stabilization time varied from 2 to 6 hours and is presented in the 
glucose graph. C. pH stability in the donor chamber. 
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Figure 10. Changes in absorbance at 280 nm with ProxiCor™ , positive control and negative control. As the 
absorbance measurements with ProxiCor™ were higher than with positive control, the amount of proteins passed was 
not directly readable from the change in absorbance. 
 
 
Figure 11. A. After incubation with ProxiCor™, the samples were collected from the donor chamber (blue) and 
receptor chamber (red) and run through SDS-page. The values present the areas of the histogram bars and values that 
differ between chambers are highlighted. Blue ones are overrepresented in the donor side and red ones are 
overrepresented in the receptor side.  B. To confirm an assumption that ProxiCor™ itself releases proteins, the 
membrane itself was incubated in NaCl for 24 hours and concentrated sample (green) was run through SDS-page. 
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4.2. Effect of biomembrane permeability on cell viability and 
proliferation 
To study the effects of biomembrane permeability on cell viability and proliferation, the optimal 
conditions were determined. The optimal conditions were considered as conditions where the serum 
addition had the greatest effect on cell cycle phases after starvation period. Although the viability 
decreased as serum starvation prolonged, the effects of serum additions on cell cycle phases 
enhanced. The greatest effects can be detected after 7 days serum starvation and 10 % serum 
addition. The viability measurements and cell cycle phase analyses of different test conditions are 
presented in Figure 12. 
 
Figure 12. A. Cell viability measurements after varying serum starvation days and FBS additions of varying strengths. 
B. Cell cycle phase measurements after different test conditions. A normal cell culture without serum starvation and 
5 % FBS addition was considered as a control for A and B. 
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The effects of biomembrane permeability on cell viability and proliferation were examined for 
ProxiCor™ and negative control membranes (Figure 13). As the ProxiCor™ was found to be 
permeable, no positive control membrane was investigated. Based on the examination of the 
optimal conditions, the HEK-293 cell solution in Leibovitz L-15 media was inserted to the donor 
chamber after 7 days serum starvation and the Leibovitz L-15 media with 10% FBS addition was 
inserted to the receptor chamber. The samples were collected and analyzed after 24 hours 
incubation. pH in the donor chamber and the receptor chamber was also measured after incubation 
to study the stability of pH. Use of ProxiCor™ allowed serum access to the cells, which was 
reflected in reduced viability. However, the pH was leveled with ProxiCor™ as it enables the 
movement of small molecules. With impermeable membrane, most of the cells remained in G1 
phase, while with ProxiCor™ the serum accessibility enhanced the cell proliferation and increased 
the number of cells in S phase. 
 
 
Figure 13.  A. Effects of 24 hours incubation with 10% FBS to cell viability with permeable ProxiCor™ and 
impermeable membrane (NEG). The bars present the percentage of trypan blue negative cells, which were considered as 
live cells, in cell suspension. B. The difference in pH between the donor and the receptor chamber with ProxiCor™ and 
impermeable membrane. C.  Distribution of the cell cycle phases after the incubation.  
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The ProxiCor™  membrane was studied also without the FBS addition to investigate whether 
the proteins, released from the membrane itself, affect the cell cycle. To exclude the effect of small 
molecule movement, a dialysis membrane with MWCO value of 0,1-0,5 kDa was examined 
alongside. Although the number of cells in S phase slightly increased compared to impermeable 
membrane, the results did not differ between the ProxiCor™ and the dialysis membrane. Thus, the 
proteins released from ProxiCor™ do not in themselves promote cell proliferation. Results are 
presented in Figure 14. 
 
Figure 14. The ProxiCor™ was also investigated without the serum addition to determine the effects of protein released 
from the membrane itself. The effects of dialysis membrane with 0,1-0,5 kDa molecular weight cut-off (MWCO) was 
investigated alongside. 
5. Discussion  
5.1. The properties of ProxiCor™  
The built test set up was evaluated by investigating the properties of the ProxiCor™ membrane. 
Unlike expected, the ProxiCor™ membrane resulted to be permeable both for proteins and small 
molecules. The movement rates of small molecules were slower with ProxiCor™ membrane 
compared to positive control of 0.4 µm pores, but the movement was still effective. With small 
molecules such as lactate, which has a molecular weight (MW) of 90 Da, the equilibrium could be 
detected within 10 hours and with larger molecules, such as glucose (MW 180 Da), within 13 hours. 
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The protein movement through ProxiCor™ was not reliably measurable with the 
spectrophotometer, since the membrane itself degraded and released proteins. However, the SDS-
page revealed that ProxiCor™ is also permeable to proteins. Protein size did not affect the 
permeability within the used range, but some affecting factors were present since the distribution of 
proteins was not similar in both sides of the membrane. This might be due the 3D architecture or the 
charge of the protein. The identification of the unequally distributed proteins might provide us with 
important information about the factors affecting the protein permeability through the ProxiCor™ 
biomembrane. This information could be utilized in the development of an improved membrane 
with selective permeability with which the secreted proteins could be retained under the membrane 
and the beneficial effects of the transplanted cells’ or micrografts’ secretome could be maximized. 
In 2004, Sariakaya et al. and Li et al. reported beneficial effects of SIS-ECM degradation 
products to host responses. However, the cell cycle analyses between a ProxiCor™ and a dialysis 
membrane, which allows only small molecule movement, did not differ, while the movement of 
small molecules slightly induced the cell proliferation compared to impermeable membrane. The 
lactate measurements after incubations (data not shown) also indicated that acceleration in cell 
metabolism, which can be detected by increase in lactate production, is dependent on the presence 
of the serum and not the ProxiCor™ itself or the dialysis membrane elicit the response. 
Even if the tissue is not serum-starved during AAMs patch preparation, the processing does 
expose the tissue and micrografts to stressful conditions. The stress upon transplantation and 
exposure to tissue and pericardial fluid can be compared, at least to some extent, to stress from 
serum restimulation, which has been reported in several studies to cause cell death. In 2015, Gao et 
al. reported active ferrotopsis when adding serum to the cell culture after serum and amino acid 
starvation. However, in their experiments the restimulation with dialyzed FBS containing only 
small molecules of serum did not enhance cell death. In addition, the reports from Sarikaya et al. 
(2004) and Li et al. (2004) highlighted the importance of low molecular weight proteome. In the 
report of Sariakya et al., the antibacterial effects from SIS-ECM were due the low-molecular weight 
fractions from 5 to 16 kDa, while the molecular weight of released components from SIS-ECM 
varied from less than 4 kDa to over 100 kDa. Li et al. also reported same molecular weight fraction 
to activate the recruitment of heart endothelial cells in vitro. Overall, the low-molecular weight 
serum proteome is attracting increasing interest in proteomics. The most abundant proteins in serum 
range from 50 kDa to 100 kDa comprising over 99% of the whole serum proteome (Bellei et al., 
2011). Figure 15 presents several molecules which are known to participate in proliferation, 
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angiogenesis and cell migration as well as inflammatory responses. The cut-off of high-molecular 
weight proteome (MW over 50 kDa) may inhibit or decrease the shock of processed cells while 
retaining the positive outcomes of AAMs patch. This is something that should be addressed in 
further investigations. 
 
Figure 15. Molecular weights (MW) of  molecules affecting the cell proliferation and viability. The drop off MW over 
50 kDa (marked as a red line) may inhibit or decrease the shock and thus be beneficial to cellular responses . 
5.2. Advantages of the test set up 
The aim of this Master's thesis was to build a test set up to study biomembrane properties. The 
results on ProxiCor™, proved the functionality of the test set up.  While studying the optimum 
properties for epicardial patch, the test set up can be utilized for several research approaches in the 
fields of biomembrane development, in vitro studies or measurement methodology development 
(Figure 16). 
The test set up can support tissue engineering, which determines the biomembrane design and 
properties. Biomembranes should share the native three-dimensional (3D) structure, surface 
properties and mechanical strength of heart tissue. As a material, synthetic or natural polymers set 
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different challenges to tissue engineering. Synthetic polymers can be fabricated homogeneously, 
and the scaffold structure can be designed to achieve improved mechanical tolerance with desired 
porosity and surface properties. However, this can lead to reduced bioactivity. Scaffolds of 
biological origin, usually composed of ECM or purified individual components of it, are usually 
considered to be biodegradable and biocompatible. The challenges with natural polymers are that 
homogenous and reproducible structures can be challenging to achieve. (Pattar, Hassanabad & 
Fedak, 2019.) Traditionally fibers have been cultured with cells to form a scaffold (Carrier et al., 
1999), but more advanced ways to control the scaffold manufacturing are electrospinning and rotary 
jet spinning. In electrospinning, micro- or nano-sized fibers are created by charging the polymer 
stream electrically and these fibers are then collected to form a scaffold. Electrospun membranes, 
made for example from PLA, polyurethane or albumin fibers, have been shown to be promising 
scaffold materials for cardiac-tissue engineering (Hosseinkhani et al., 2010; Kaiser et al., 2017; 
Fleischer et al., 2017 ). While hunting for the perfect biomembrane for the epicardial patch, the 
effects of scaffold design to diffusion properties and cell responses are easily compared with our 
standardized test set up. 
 
Figure 16. The biomembrane test set up, which was built in this  Master’s thesis, enables several research possibilities 
before entering the preclinical or clinical phases. Not only biomembrane permeability can be tested, but also the 
degradation of biomembranes and cell responses to degradation products can be examined. With appropriate 
arrangements, cell responses to biomembranes with loaded nanoparticles or small molecules can be studied real-time. 
There also is a constant need for new real-time measurement methods, which can easily be tested with described 
system.  
  
35  
 
 
 
 
 
Besides to permeability testing, the test set up offers a possibility to study the degradation of a 
given biomembrane and examine how the degradation products affect cells. In addition to the 
degradation products from biomembrane itself, a rising trend is to load biomembranes with small 
molecules, drugs or nanoparticles, which release during degradation. The effects of released 
molecules can be studied real-time or at different time points and the experiments are easily 
repeated with different solutions or cell types. The gained information on how different cell types 
respond to different stimuli, can be used to develop the biomembrane or patch treatments towards a 
more personal direction. Not all patients can be studied individually, but the cell responses to 
treatment can be studied among different patients' groups with different disease backgrounds. The 
effects of the environment can be easily examined by moving the test set up into the desired 
environments, for example hypoxic conditions can be achieved by moving the system into an 
oxygen-level-controlled incubator. 
Currently, further studies on the proteome secreted by engrafted cells, is not feasible due to the 
requirements of needed protein amounts and issues related to overloaded proteins, such as albumin 
or immunoglobulins, in the sample. The test set up offers a possibility to concentrate the proteins by 
changing the media in the receptor chamber without disturbing the cells in the donor chamber. By 
providing energy sources and removal of end-products of cellular metabolism, the test set up 
enhances the cell wellbeing and provides favorable conditions for increased secretion of proteins. 
While retaining the secretome in the donor chamber, the concentration of secreted proteins 
increases and can thus allow further investigations.  
5.3. Limitations and improvements of the test set up  
This first version of the test set up serves as a solid background for further modifications to yield 
results from different biomembranes and cell types as well as to integrate additional measurements 
to further characterize both the biomembrane properties as well as the cellular metabolic responses.  
The flow cell-based biosensor, with individual pump, is susceptible for disturbance. This can be 
detected as sudden increases and decreases in glucose and lactate concentrations (Figure 9). Instead 
of using flow cell-type biosensors, there are strip-based sensors, which can be inserted straight to 
the chambers, and the use of individual pumps can be avoided. This type of direct measurement 
could stabilize the biosensor faster in the beginning of the test and also stabilize the real-time 
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measurements. However, as with all biosensors, it must be ensured that no harmful agents are 
released from the sensor to affect the cells in the test set up. The absence of the pump also affects 
the liquid amount in a system, since in the tubing there are always a dead volume, which affects the 
concentration gradient between chambers. The used buffer solution, PBS, was not recommended by 
the biosensor manufacturer, instead it could be replaced with a bicarbonate buffer to achieve more 
stable measurements. 
The temperature has a great effect on diffusion rates and biological responses, and it should also 
be measured in real-time. The currently used pH meter has a temperature sensor, but the fluid level 
in the chamber is too low to get accurate results. One possibility is to replace the currently used pH 
meter with another sensor, which could measure the temperature from small liquid amounts. In 
addition, some biosensors have the possibility to measure temperature and that might be another 
way to add the real-time temperature measurement to the test set up. 
Currently, the tubing, from the receptor chamber to the spectrophotometer and back, is long and 
wide and thus the dead volume in the system increases the liquid volume in the receptor chamber to 
approximately 1 ml. As with the biosensor, this affects the concentration gradients of the system. In 
the future, a smaller spectrophotometer with shorter, thinner tubing could provide more accurate 
results. The smaller size of the spectrophotometer could also improve mobility of the test set up. For 
more precise follow up of protein movement, there could be more than just one spectrophotometer 
connected. A sample, taken at certain time points, could be led to a branch that divides the sample 
into several portions. Each portion could then be passed through a membrane of varying MWCO 
and then be detected with a single wavelength (280 nm) spectrophotometer. This could give us 
more information about the size distribution of proteins. Size exclusion liquid chromatography 
would probably give more accurate results with smaller sample size, but it is difficult to place it in 
the current system without giving up the advantages of the system, such as easy mobility. 
HEK-293 cells were used in this study because they are easy to grow and are commonly used in 
research as model cells. These cells differ in many ways from cells of the cardiac tissue. For 
example, the levels of the cell surface transporter proteins for glucose, lactate and fatty acids, as 
listed in Table 2, are very different in the HEK-293 cells than in the heart tissue. This is something 
that should be considered while interpreting the cell responses. In addition to HEK-293 cells, 
cardiomyocytes grown on microcarrier beads can be inserted as a suspension to the test set up to 
improve comparability. Carefully regulated metabolism of cells can be achieved by optogenetically 
treated cardiomyocytes which also enables response studies during contraction (Pastrana, 2011; 
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Björk et al., 2017). Eventually, the tissue pieces from atrial appendage could be used to study heart 
tissue instead of just one individual cell line. 
Table 2. Comparison of solute carrier transport protein gene expression levels in HEK-293 cells and in heart tissue. The 
proteins which are over-presented in HEK-293 cells, compared to heart tissue, are marked as red (HEK-293/Heart tissue 
ratio >1.5) and proteins and proteins which are under-presented in HEK-293 cells, compared to the heart tissue, are 
marked as blue (HEK-293/Heart tissue ratio <0.5).  
 
 
After the experimental incubation, the biomembrane itself is an important subject of studies. 
Currently, the imaging of nanosized pores and structures is challenging. The field emission 
scanning electron microscopy (FE-SEM) is usually used in the imaging of thin membranes, but the 
resolution (0.4 nm) is not necessarily enough. Transmission electron microscopy (TEM) has better 
resolution (0.2 nm), but with thin membranes the sample preparation is difficult. Atomic force 
microscopy (AFM) is used to study biological membranes and could be utilized for this purpose. In 
addition, during incubation the cells can attach to the biomembrane and thus the histological 
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staining of biomembrane can offer an important information about the interactions between cells 
and the biomembrane. 
6. Conclusions 
This Master’s thesis describes a test set up, which can be used to experimentally test selected 
properties of biomembranes. The movement of small molecules and proteins are easily followed 
real-time together with pH recording. The test set up was evaluated by examining the properties of 
ProxiCor™, a biomembrane currently used in the AAMs patch. As a result, the ProxiCor™ 
demonstrated permeability both for small molecules and for proteins. It also stabilized pH compared 
to an impermeable membrane. Overall, the results prove the functionality of the test set up as an 
experimental tool for biomembrane characterization. The test set up can easily be further developed 
in compactness, mobility, cell culture incubator compatibility and incorporation of measurements of 
additional parameters. With the help of this set up, therapeutic biomembrane components of 
epicardial patches can be investigated, evaluated and their optimal requirements identified. 
Cell therapies have been investigated in the treatment of heart failure since the early 1990’s. 
Many positive outcomes have been reported but overall the results are mixed. One of the most 
influencing factors is the delivery of cells. Traditionally used injection-based techniques are often 
reported to have poor cell retention and survival. Patch-based techniques have not just shown to 
improve the cell retention, but also support the heart mechanically while utilizing the paracrine 
effects more effectively compared to injections. In addition to being just a carrier and cover for 
grafted cells, the biomembrane in the patch has a great impact on the cell response. In future, it is a 
challenge to develop a biomembrane which provides ideal environment for the grafted cells and 
further supports the scar tissue reverse remodeling. With described test set up we are one step closer 
to the perfect biomembrane and thus closer to solution of how to repair a scarred heart. 
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